531660 Sigma-AldrichGCase Activator, NCGC00188758 - Calbiochem
Sinónimos: N-(4-Ethynylphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide, Glucocerebrosidase Activator, Glucocerebrosidase Chemical Chaperone, NCGC758
Descripción
| Replacement Information |
|---|
Tabla espec. clave
| Empirical Formula |
|---|
| C₁₇H₁₄N₄O |
Precios y disponibilidad
| Número de referencia | Disponiblidad | Embalaje | Cant./Env. | Precio | Cantidad | |
|---|---|---|---|---|---|---|
| 5.31660.0001 |
|
Frasco de vidrio | 10 mg |
|
— |
| References | |
|---|---|
| References | Aflaki, E., et al. 2014. Sci. Transl. Med. 6, 240ra73. Patnaik, S., et al. 2012. J. Med. Chem. 55, 5734. |
| Product Information | |
|---|---|
| Form | Light orange powder |
| Hill Formula | C₁₇H₁₄N₄O |
| Chemical formula | C₁₇H₁₄N₄O |
| Reversible | Y |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | Glucocerebrosidase (Gcase) |
| Purity | ≥98% by HPLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | Y |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Número de referencia | GTIN |
| 5.31660.0001 | 04055977259988 |
Documentation
GCase Activator, NCGC00188758 - Calbiochem Ficha datos de seguridad (MSDS)
| Título |
|---|
Referencias bibliográficas
| Visión general referencias |
|---|
| Aflaki, E., et al. 2014. Sci. Transl. Med. 6, 240ra73. Patnaik, S., et al. 2012. J. Med. Chem. 55, 5734. |
Folleto
| Cargo |
|---|
| NPI Flyer- Epigenetics and Nuclear Function Feature |
| New Products - Antibodies, Small Molecule, Inhibitors |
Licencias necesarias e Información técnica
| Cargo |
|---|
| White Paper: Further considerations of antibody validation and usage. |


